Richard S. Finn, MD
A trio of CDK 4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)—have continued to revolutionize the field of breast cancer, explained Richard S. Finn, MD.
, Finn, an associate professor of medicine at the Geffen School of Medicine at the University of California, Los Angeles, covers the evolution of CDK 4/6 inhibition in the field of breast cancer and appropriate patient selection for this type of therapy.
OncLive: Can you share the history of CDK 4/6 inhibitor development in breast cancer?
The field has changed very quickly in a short period of time after decades of, really, no real novel approaches in first-line ER-positive breast cancer—let alone hormone-resistant breast cancer. We now have 3 CDK 4/6 inhibitors approved. Several years ago [we were] talking about CDK 4/6 inhibitors in a time where we only had very early data with palbociclib, which came out of preclinical work done by Dr Dennis Slamon and myself in collaboration with Pfizer. That led to the PALOMA-1 trial and, eventually, the accelerated approval of palbociclib and letrozole.
... to read the full story